<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00669669</url>
  </required_header>
  <id_info>
    <org_study_id>2000.00</org_study_id>
    <secondary_id>NCI-2013-00701</secondary_id>
    <secondary_id>8357</secondary_id>
    <secondary_id>2000.00</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>RG1709046</secondary_id>
    <nct_id>NCT00669669</nct_id>
  </id_info>
  <brief_title>O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas</brief_title>
  <official_title>Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and best dose of temozolomide when given&#xD;
      together with radiation therapy, carmustine, O6-benzylguanine, and patients' own stem cell&#xD;
      (autologous) transplant in treating patients with newly diagnosed glioblastoma multiforme or&#xD;
      gliosarcoma. Giving chemotherapy, such as temozolomide, carmustine, and O6-benzylguanine, and&#xD;
      radiation therapy before a peripheral stem cell transplant stops the growth of cancer cells&#xD;
      by stopping them from dividing or killing them. Giving colony-stimulating factors, such as&#xD;
      filgrastim or plerixafor, and certain chemotherapy drugs, helps stem cells move from the bone&#xD;
      marrow to the blood so they can be collected and stored. Chemotherapy or radiation therapy is&#xD;
      then given to prepare the bone marrow for the stem cell transplant. The stem cells are then&#xD;
      returned to the patient to replace the blood-forming cells that were destroyed by the&#xD;
      chemotherapy and radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the safety and feasibility of infusing autologous granulocyte colony-stimulating&#xD;
      factor (G-CSF) (filgrastim) mobilized stem cells transduced with a Phoenix-gibbon ape&#xD;
      leukemia virus (GALV)-pseudotype vector expressing methylguanine methyltransferase (MGMT)&#xD;
      (P140K).&#xD;
&#xD;
      II. Define the dose of BCNU (carmustine) that results in efficient engraftment of gene&#xD;
      modified cells when given with peripheral blood stem cell support.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the engraftment of gene-modified cells after conditioning with BCNU.&#xD;
&#xD;
      II. Determine the ability to select gene-modified cells in vivo with this regimen.&#xD;
&#xD;
      III. Evaluate the molecular and clonal composition of gene-modified cells after chemotherapy&#xD;
      with temozolomide.&#xD;
&#xD;
      IV. Observe patients for clinical anti-tumor response.&#xD;
&#xD;
      V. Determine the correlation of the level of MGMT (P140K) marking with toxicity, temozolomide&#xD;
      dose achieved, and response.&#xD;
&#xD;
      VI. Characterize the toxicity associated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a phase I, dose-escalation study of temozolomide followed by a phase II&#xD;
      study.&#xD;
&#xD;
      PART I: Within 35 days of surgery, patients undergo 3 dimensional (3D) conformal&#xD;
      intensity-modulated radiation therapy (IMRT) or proton beam radiation therapy daily 5 days&#xD;
      per week for 6 weeks. Patients receive filgrastim subcutaneously (SC) on days -7 to -3 and&#xD;
      begin stem cell collection on the 4th day of filgrastim administration (up to 3 apheresis).&#xD;
      Patients may also receive plerixafor SC on days -5 to -3. The CD34+ stem cells are separated&#xD;
      from the patient's stem cells and they are transduced with Phoenix-RD114 pseudotype vector&#xD;
      (retrovirus). One day after apheresis is completed, patients receive carmustine intravenously&#xD;
      (IV) over 3 hours followed 2 hours later by temozolomide orally (PO). At least twenty-four&#xD;
      hours after completion of carmustine and temozolomide, patients undergo reinfusion of&#xD;
      genetically-modified stem cells.&#xD;
&#xD;
      PART II: Beginning approximately 4 weeks after completion of Phase 1 of the study, patients&#xD;
      receive O6-benzylguanine IV continuously over 48 hours followed by temozolomide PO within 1&#xD;
      hour. Treatment may repeat at least every 28 days for a total of 24 courses in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 1-3 months for 2 years,&#xD;
      every 3-6 months for 3 years, and then annually thereafter for 10 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 25, 2009</start_date>
  <completion_date type="Actual">January 20, 2021</completion_date>
  <primary_completion_date type="Actual">July 6, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Dose-limiting Toxicity (DLT)</measure>
    <time_frame>Up to 6 weeks after infusion</time_frame>
    <description>Defined as any grade 4 nonhematopoietic toxicity that is likely related to the investigational procedures (Part I)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Retrovirus or Leukemia</measure>
    <time_frame>Up to 2 years after infusion</time_frame>
    <description>Replication competent retrovirus or diagnosis of leukemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Proportion of patients with reduction in tumor burden of a predefined amount</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>From the onset of temozolomide to the date at which unequivocal disease progression, assessed up to 15 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Survived</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>From the first day of treatment until death, assessed up to 15 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>From the first day of treatment until unequivocal progression is documented, assessed up to 15 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene Transfer Efficiency and in Vivo Selection</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Assessed by gene marking in peripheral blood and marrow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Chemoprotection</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>assessed by the ability to increase the Temozolomide dose beyond 472 mg/m^2</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Gliosarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-Dimensional Conformal Radiation Therapy</intervention_name>
    <description>Undergo 3D conformal IMRT</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>3-dimensional radiation therapy</other_name>
    <other_name>3D CONFORMAL RADIATION THERAPY</other_name>
    <other_name>3D CRT</other_name>
    <other_name>3D-CRT</other_name>
    <other_name>Conformal Therapy</other_name>
    <other_name>Radiation Conformal Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous in vitro-treated peripheral blood stem cell transplant</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>Autologous Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>BCNU</other_name>
    <other_name>Becenum</other_name>
    <other_name>Becenun</other_name>
    <other_name>BiCNU</other_name>
    <other_name>Bis(chloroethyl) Nitrosourea</other_name>
    <other_name>Bis-Chloronitrosourea</other_name>
    <other_name>Carmubris</other_name>
    <other_name>Carmustin</other_name>
    <other_name>Carmustinum</other_name>
    <other_name>FDA 0345</other_name>
    <other_name>Gliadel</other_name>
    <other_name>N,N'-Bis(2-chloroethyl)-N-nitrosourea</other_name>
    <other_name>Nitrourean</other_name>
    <other_name>Nitrumon</other_name>
    <other_name>SK 27702</other_name>
    <other_name>SRI 1720</other_name>
    <other_name>WR-139021</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>Filgrastim XM02</other_name>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
    <other_name>rG-CSF</other_name>
    <other_name>Tbo-filgrastim</other_name>
    <other_name>Tevagrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>In Vitro-Treated Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Undergo autologous in vitro-treated peripheral blood stem cell transplant</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>in vitro-treated PBPC transplantation</other_name>
    <other_name>in vitro-treated peripheral blood progenitor cell transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy</intervention_name>
    <description>Undergo 3D conformal IMRT</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>IMRT</other_name>
    <other_name>Intensity Modulated RT</other_name>
    <other_name>Intensity-Modulated Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>O6-Benzylguanine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>6-O-BENZYLGUANINE</other_name>
    <other_name>O(6)-Benzylguanine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plerixafor</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>AMD 3100</other_name>
    <other_name>JM-3100</other_name>
    <other_name>Mozobil</other_name>
    <other_name>SDZ SID 791</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Beam Radiation Therapy</intervention_name>
    <description>Undergo proton beam radiation therapy</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (chemotherapy, autologous stem cell transplant)</arm_group_label>
    <other_name>CCRG-81045</other_name>
    <other_name>Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-</other_name>
    <other_name>M &amp; B 39831</other_name>
    <other_name>M and B 39831</other_name>
    <other_name>Methazolastone</other_name>
    <other_name>RP-46161</other_name>
    <other_name>SCH 52365</other_name>
    <other_name>Temcad</other_name>
    <other_name>Temodal</other_name>
    <other_name>Temodar</other_name>
    <other_name>Temomedac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with glioblastoma multiforme or gliosarcoma&#xD;
&#xD;
          -  The patient or legal guardian must be able to comprehend the informed consent form and&#xD;
             sign prior to patient enrollment&#xD;
&#xD;
          -  Karnofsky performance status at time of study entry must be &gt;= 70%&#xD;
&#xD;
          -  Life expectancy of &gt;= 3 months&#xD;
&#xD;
          -  Patients must agree to undergo repeat clinical neurological examinations and brain&#xD;
             magnetic resonance imaging (MRI) with appropriate contrast after every other cycle of&#xD;
             chemotherapy&#xD;
&#xD;
          -  White blood cell (WBC) &gt; 3000/ul&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt; 1500/ul&#xD;
&#xD;
          -  Platelets &gt; 100,000/ul&#xD;
&#xD;
          -  Hemoglobin &gt; 10 gm/100ml&#xD;
&#xD;
          -  Total and direct bilirubin &lt; 1.5 times upper limit of laboratory normal&#xD;
&#xD;
          -  Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate&#xD;
             transaminase (SGPT) =&lt; 3 times upper limit of laboratory normal&#xD;
&#xD;
          -  Alkaline phosphatase =&lt; 3 times upper limit of laboratory normal&#xD;
&#xD;
          -  Blood urea nitrogen (BUN) &lt; 1.5 times upper limit of laboratory normal&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 times upper limit of laboratory normal&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &gt;= 40%, however, subjects with a LVEF in the&#xD;
             range of 40-49% should have cardiology clearance prior to intervention&#xD;
&#xD;
          -  MGMT promoter methylation analysis of surgically resected tumor or tumor biopsy must&#xD;
             demonstrate an unmethylated or hypomethylated MGMT promoter status&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with cardiac insufficiency and a LVEF of &lt; 40%; history of coronary artery&#xD;
             disease or arrhythmia, which has required or requires ongoing treatment&#xD;
&#xD;
          -  Patients with active pulmonary infection and/or pulse oximetry &lt; 90% and a corrected&#xD;
             diffusion capacity of the lung for carbon monoxide (DLCO) &lt; 70% of predicted&#xD;
&#xD;
          -  Active systemic infection&#xD;
&#xD;
          -  Patients who are human immunodeficiency virus (HIV) positive&#xD;
&#xD;
          -  Pregnant or lactating women; a beta-human chorionic gonadotropin (HCG) level will be&#xD;
             obtained from women of childbearing potential; fertile men and women should use&#xD;
             effective contraception&#xD;
&#xD;
          -  Previous chemotherapy for any malignancy including temozolomide, dacarbazine (DTIC) or&#xD;
             prior nitrosourea&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Bleeding disorder&#xD;
&#xD;
          -  Methylated or hypermethylated MGMT promoter status within tumor tissue&#xD;
&#xD;
          -  Medical or psychiatric condition which in the opinion of the protocol chairman would&#xD;
             compromise the patient's ability to tolerate this protocol&#xD;
&#xD;
          -  Prior interstitial radiotherapy, stereotactic or gamma knife surgery or implanted&#xD;
             BCNU-wafers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Peter Kiem</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 29, 2008</study_first_submitted>
  <study_first_submitted_qc>April 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2008</study_first_posted>
  <results_first_submitted>November 7, 2018</results_first_submitted>
  <results_first_submitted_qc>December 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 28, 2018</results_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plerixafor</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>O(6)-benzylguanine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 20, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT00669669/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Chemotherapy, Autologous Stem Cell Transplant)</title>
          <description>See Detailed Description&#xD;
3-Dimensional Conformal Radiation Therapy: Undergo 3D conformal IMRT&#xD;
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous in vitro-treated peripheral blood stem cell transplant&#xD;
Carmustine: Given IV&#xD;
Filgrastim: Given SC&#xD;
In Vitro-Treated Peripheral Blood Stem Cell Transplantation: Undergo autologous in vitro-treated peripheral blood stem cell transplant&#xD;
Intensity-Modulated Radiation Therapy: Undergo 3D conformal IMRT&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
O6-Benzylguanine: Given IV&#xD;
Plerixafor: Given SC&#xD;
Proton Beam Radiation Therapy: Undergo proton beam radiation therapy&#xD;
Temozolomide: Given PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>To late to start treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Chemotherapy, Autologous Stem Cell Transplant)</title>
          <description>See Detailed Description&#xD;
3-Dimensional Conformal Radiation Therapy: Undergo 3D conformal IMRT&#xD;
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous in vitro-treated peripheral blood stem cell transplant&#xD;
Carmustine: Given IV&#xD;
Filgrastim: Given SC&#xD;
In Vitro-Treated Peripheral Blood Stem Cell Transplantation: Undergo autologous in vitro-treated peripheral blood stem cell transplant&#xD;
Intensity-Modulated Radiation Therapy: Undergo 3D conformal IMRT&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
O6-Benzylguanine: Given IV&#xD;
Plerixafor: Given SC&#xD;
Proton Beam Radiation Therapy: Undergo proton beam radiation therapy&#xD;
Temozolomide: Given PO</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Dose-limiting Toxicity (DLT)</title>
        <description>Defined as any grade 4 nonhematopoietic toxicity that is likely related to the investigational procedures (Part I)</description>
        <time_frame>Up to 6 weeks after infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Autologous Stem Cell Transplant)</title>
            <description>See Detailed Description&#xD;
3-Dimensional Conformal Radiation Therapy: Undergo 3D conformal IMRT&#xD;
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous in vitro-treated peripheral blood stem cell transplant&#xD;
Carmustine: Given IV&#xD;
Filgrastim: Given SC&#xD;
In Vitro-Treated Peripheral Blood Stem Cell Transplantation: Undergo autologous in vitro-treated peripheral blood stem cell transplant&#xD;
Intensity-Modulated Radiation Therapy: Undergo 3D conformal IMRT&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
O6-Benzylguanine: Given IV&#xD;
Plerixafor: Given SC&#xD;
Proton Beam Radiation Therapy: Undergo proton beam radiation therapy&#xD;
Temozolomide: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Dose-limiting Toxicity (DLT)</title>
          <description>Defined as any grade 4 nonhematopoietic toxicity that is likely related to the investigational procedures (Part I)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Retrovirus or Leukemia</title>
        <description>Replication competent retrovirus or diagnosis of leukemia</description>
        <time_frame>Up to 2 years after infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Autologous Stem Cell Transplant)</title>
            <description>See Detailed Description&#xD;
3-Dimensional Conformal Radiation Therapy: Undergo 3D conformal IMRT&#xD;
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous in vitro-treated peripheral blood stem cell transplant&#xD;
Carmustine: Given IV&#xD;
Filgrastim: Given SC&#xD;
In Vitro-Treated Peripheral Blood Stem Cell Transplantation: Undergo autologous in vitro-treated peripheral blood stem cell transplant&#xD;
Intensity-Modulated Radiation Therapy: Undergo 3D conformal IMRT&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
O6-Benzylguanine: Given IV&#xD;
Plerixafor: Given SC&#xD;
Proton Beam Radiation Therapy: Undergo proton beam radiation therapy&#xD;
Temozolomide: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Retrovirus or Leukemia</title>
          <description>Replication competent retrovirus or diagnosis of leukemia</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate</title>
        <description>Proportion of patients with reduction in tumor burden of a predefined amount</description>
        <time_frame>Up to 15 years</time_frame>
        <posting_date>12/2027</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>From the onset of temozolomide to the date at which unequivocal disease progression, assessed up to 15 years</description>
        <time_frame>Up to 15 years</time_frame>
        <posting_date>12/2027</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Survived</title>
        <description>From the first day of treatment until death, assessed up to 15 years</description>
        <time_frame>Up to 15 years</time_frame>
        <posting_date>12/2027</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>From the first day of treatment until unequivocal progression is documented, assessed up to 15 years</description>
        <time_frame>Up to 15 years</time_frame>
        <posting_date>12/2027</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gene Transfer Efficiency and in Vivo Selection</title>
        <description>Assessed by gene marking in peripheral blood and marrow</description>
        <time_frame>Up to 15 years</time_frame>
        <posting_date>12/2027</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Chemoprotection</title>
        <description>assessed by the ability to increase the Temozolomide dose beyond 472 mg/m^2</description>
        <time_frame>Up to 15 years</time_frame>
        <posting_date>12/2027</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events are collected until through study completion on average 2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Chemotherapy, Autologous Stem Cell Transplant)</title>
          <description>See Detailed Description&#xD;
3-Dimensional Conformal Radiation Therapy: Undergo 3D conformal IMRT&#xD;
Autologous Hematopoietic Stem Cell Transplantation: Undergo autologous in vitro-treated peripheral blood stem cell transplant&#xD;
Carmustine: Given IV&#xD;
Filgrastim: Given SC&#xD;
In Vitro-Treated Peripheral Blood Stem Cell Transplantation: Undergo autologous in vitro-treated peripheral blood stem cell transplant&#xD;
Intensity-Modulated Radiation Therapy: Undergo 3D conformal IMRT&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
O6-Benzylguanine: Given IV&#xD;
Plerixafor: Given SC&#xD;
Proton Beam Radiation Therapy: Undergo proton beam radiation therapy&#xD;
Temozolomide: Given PO</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Heme &amp; Lymphatics</sub_title>
                <counts group_id="E1" events="162" subjects_affected="11" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>HEENT</sub_title>
                <counts group_id="E1" events="57" subjects_affected="5" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Digestive</sub_title>
                <counts group_id="E1" events="18" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic &amp; Nutritional</sub_title>
                <counts group_id="E1" events="155" subjects_affected="11" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="15" subjects_affected="6" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous</sub_title>
                <counts group_id="E1" events="43" subjects_affected="8" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Urogenital</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin &amp; Appendages</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hans-Peter Kiem, M.D., Ph.D.</name_or_title>
      <organization>Fred Hutch Cancer Research Center</organization>
      <phone>206.667.4425</phone>
      <email>hkiem@fredhutch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

